Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
This launch is part of the company's strategy to expand its nutraceutical portfolio
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
Subscribe To Our Newsletter & Stay Updated